Fresenius’ Q2 figures benefited from good organic growth across all divisions, but profitability development showed a mixed picture. Kabi was a (still) positive surprise, Helios moderated as expected and FMC was hit by various expected as well as unexpected issues. Vamed became a small but shining star. Reported figures were more or less in line with our expectations and consensus was also broadly met. The higher top-line guidance is quite nice, but profitability is barely expected to f
30 Jul 2019
Quite nice organic growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Quite nice organic growth
Fresenius SE & Co. KGaA (FRE:WBO) | 0 0 0.5% | Mkt Cap: 35,173m
- Published:
30 Jul 2019 -
Author:
Martin Schnee -
Pages:
3
Fresenius’ Q2 figures benefited from good organic growth across all divisions, but profitability development showed a mixed picture. Kabi was a (still) positive surprise, Helios moderated as expected and FMC was hit by various expected as well as unexpected issues. Vamed became a small but shining star. Reported figures were more or less in line with our expectations and consensus was also broadly met. The higher top-line guidance is quite nice, but profitability is barely expected to f